Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT06353022
Title Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma (IFm2022-01)
Acronym IFm2022-01
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Nantes University Hospital
Age Groups: senior | adult
Covered Countries FRA

No variant requirements are available.